BYON4228 is a pan-allelic antagonistic SIRPα antibody that potentiates destruction of antibody-opsonized tumor cells and lacks binding to SIRPγ on T cells

BACKGROUND: Preclinical studies have firmly established the CD47-signal-regulatory protein (SIRP)α axis as a myeloid immune checkpoint in cancer, and this is corroborated by available evidence from the first clinical studies with CD47 blockers. However, CD47 is ubiquitously expressed and mediates fu...

Descripción completa

Detalles Bibliográficos
Autores principales: van Helden, Mary J, Zwarthoff, Seline A, Arends, Roel J, Reinieren-Beeren, Inge M J, Paradé, Marc C B C, Driessen-Engels, Lilian, de Laat-Arts, Karin, Damming, Désirée, Santegoeds-Lenssen, Ellen W H, van Kuppeveld, Daphne W J, Lodewijks, Imke, Olsman, Hugo, Matlung, Hanke L, Franke, Katka, Mattaar-Hepp, Ellen, Stokman, Marloes E M, de Wit, Benny, Glaudemans, Dirk H R F, van Wijk, Daniëlle E J W, Joosten-Stoffels, Lonnie, Schouten, Jan, Boersema, Paul J, van der Vleuten, Monique, Sanderink, Jorien W H, Kappers, Wendela A, van den Dobbelsteen, Diels, Timmers, Marco, Ubink, Ruud, Rouwendal, Gerard J A, Verheijden, Gijs, van der Lee, Miranda M C, Dokter, Wim H A, van den Berg, Timo K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Basic Tumor Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10186489/
https://www.ncbi.nlm.nih.gov/pubmed/37068796
http://dx.doi.org/10.1136/jitc-2022-006567

Ejemplares similares

Ejemplares similares